301 Results

People

  1. Livingston
    Livingston
  2. Old
    Old
  3. Ragupathi
    Ragupathi
  4. Danishefsky
    Danishefsky
  5. Houghton
    Houghton
  6. Gnjatic
    Gnjatic
  7. Jungbluth
    Jungbluth
  8. Wolchok
    Wolchok
  9. Ritter
    Ritter
  10. Scheinberg
    Scheinberg

Groups

  1. Department of Medicine (174)
  2. Solid Tumor Oncology Division (130)
  3. Melanoma and Immunotherapeutics Service (77)
  4. GSK Faculty (76)
  5. Sloan Kettering Institute Faculty (73)
  6. Hematologic Malignancies, Division of (65)
  7. Melanoma Disease Management Team (56)
  8. Center for Hematologic Malignancies (49)
  9. Molecular Pharmacology and Chemistry Program Faculty (46)
  10. Sloan Kettering Institute Postdocs (45)
  1. "immunogenicity"
Formats
  1. Journal Article (262)
  2. Review (16)
  3. Conference Paper (6)
  4. Editorial (6)
  5. Meeting Abstract (6)
  6. Correspondence (2)
  7. Research Letter (2)
  8. Guidelines (1)
Groups
  1. Department of Medicine (174)
  2. Solid Tumor Oncology Division (130)
  3. Melanoma and Immunotherapeutics Service (77)
  4. GSK Faculty (76)
  5. Sloan Kettering Institute Faculty (73)
  6. Hematologic Malignancies, Division of (65)

More Groups

People
  1. Philip Livingston (56)
  2. Lloyd Old (54)
  3. Govindaswami Ragupathi (37)
  4. Jedd Wolchok (26)
  5. Alan Houghton (20)
  6. Samuel Danishefsky (20)

More People

Years
  1. 2025 (12)
  2. 2024 (26)
  3. 2023 (9)
  4. 2022 (9)
  5. 2021 (5)
  6. 2020 (9)

More Years

Publications
  1. Clinical Cancer Research (37)
  2. Proceedings of the National Academy of Sciences of the United States of America (13)
  3. Cancer Research (12)
  4. Cancer Immunology, Immunotherapy (11)
  5. Journal of Immunology (11)
  6. International Journal of Cancer (7)

More Publications

Publishers
  1. American Association for Cancer Research (55)
  2. Nature Publishing Group (29)
  3. Elsevier Inc. (25)
  4. Springer (18)
  5. National Academy of Sciences (13)
  6. John Wiley & Sons (12)

More Publishers

Results (301)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
    Journal Article

    Litchfield, K.; Reading, J. L.; Puttick, C.; Thakkar, K.; Abbosh, C.; Bentham, R.; Watkins, T. B. K.; Rosenthal, R.; Biswas, D.; Rowan, A.; more...
    Cell (2021)

    Fulltext@MSK | Save
  • Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
    Journal Article

    Machiels, J. P.; Gomez-Roca, C.; Michot, J. M.; Zamarin, D.; Mitchell, T.; Catala, G.; Eberst, L.; Jacob, W.; Jegg, A. M.; Cannarile, M. A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction
    Journal Article

    Wells, D. K.; van Buuren, M. M.; Dang, K. K.; Hubbard-Lucey, V. M.; Sheehan, K. C. F.; Campbell, K. M.; Lamb, A.; Ward, J. P.; Sidney, J.; Blazquez, A. B.; more...
    Cell (2020)

    Fulltext@MSK | Save
  • CAR chase: Where do engineered cells go in humans?
    Editorial

    Krebs, S.; Dacek, M. M.; Carter, L. M.; Scheinberg, D. A.; Larson, S. M.
    Frontiers in Oncology (2020)

    Fulltext@MSK | Save
  • Emerging biomarkers in urothelial carcinoma: Challenges and opportunities
    Review

    Andreatos, N.; Iyer, G.; Grivas, P.
    Cancer Treatment and Research Communications (2020)

    Fulltext@MSK | Save
  • Optimizing radiation therapy to boost systemic immune responses in breast cancer: A critical review for breast radiation oncologists
    Review

    Ho, A. Y.; Wright, J. L.; Blitzblau, R. C.; Mutter, R. W.; Duda, D. G.; Norton, L.; Bardia, A.; Spring, L.; Isakoff, S. J.; Chen, J. H.; more...
    International Journal of Radiation Oncology, Biology, Physics (2020)

    Fulltext@MSK | Save
  • Re: Alejandro Sanchez, Helena Furberg, Fengshen Kuo, et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: A cohort study. Lancet Oncol 2020;21:283–93: Unraveling the obesity paradox in immunogenic malignancies: A step toward precision oncology?
    Correspondence

    Singla, N.
    European Urology (2020)

    Fulltext@MSK | Save
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
    Journal Article

    Goldberg, A. D.; Atallah, E.; Rizzieri, D.; Walter, R. B.; Chung, K. Y.; Spira, A.; Stock, W.; Tallman, M. S.; Cruz, H. G.; Boni, J.; more...
    Leukemia Research (2020)

    Fulltext@MSK | Save
  • A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
    Journal Article

    van Brummelen, E. M. J.; Levchenko, E.; Dómine, M.; Fennell, D. A.; Kindler, H. L.; Viteri, S.; Gadgeel, S.; López, P. G.; Kostorov, V.; Morgensztern, D.; more...
    Investigational New Drugs (2020)

    Fulltext@MSK | Save
  • Immune therapy for liver cancers
    Review

    Hilmi, M.; Vienot, A.; Rousseau, B.; Neuzillet, C.
    Cancers (2020)

    Fulltext@MSK | Save